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Cancer is sustained by defects in the mechanisms underlying cell proliferation, mito-
chondrial metabolism, and cell death. Mitochondrial Ca2+ ions are central to all these
processes, serving as signaling molecules with specific spatial localization, magnitude,
and temporal characteristics. Mutations in mtDNA, aberrant expression and/or regulation
of Ca2+-handling/transport proteins and abnormal Ca2+-dependent relationships among
the cytosol, endoplasmic reticulum, and mitochondria can cause the deregulation of
mitochondrial Ca2+-dependent pathways that are related to these processes, thus
determining oncogenic behavior. In this review, we propose that mitochondrial Ca2+
remodeling plays a pivotal role in shaping the oncogenic signaling cascade, which is a
required step for cancer formation and maintenance. We will describe recent studies
that highlight the importance of mitochondria in inducing pivotal “cancer hallmarks”
and discuss possible tools to manipulate mitochondrial Ca2+ to modulate cancer
survival.
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Introduction
The mitochondrion is an endosymbiotic organelle that characterizes any eukaryotic cell, participat-
ing in many aspects of cell physiology, such as ATP production (1), intracellular Ca2+ signaling (2),
lipid metabolism (3), reactive oxygen species (ROS) production (4), inflammasome activation (5),
and cell death regulation (6).
Mitochondria can fulfill a large energy demand due to their biosynthetic capacities; during
mitochondrial respiration, it can rapidly accumulate Ca2+ through an electrogenic pathway (7) and
via their close appositionwith theCa2+-storing endoplasmic reticulum (ER) (8). Ca2+ released from
the ER generates microdomains consisting of high [Ca2+] that are sequestered by themitochondrial
Ca2+ uniporter (MCU) (9, 10).
Because of the important role of mitochondria in cell fate, many pathological conditions
are associated with mitochondrial failure, including metabolic and neurodegenerative diseases
(11), inflammation, and cancer (12). Mitochondrial dysfunction is associated with cancer devel-
opment and progression. During carcinogenesis in some malignant cells, the mitochondrial
Ca2+ signaling was significantly remodeled, compromising mitochondrial functions in ways
that caused them to overwhelm normal cells. Uncontrolled growth, programed cell death eva-
sion, metabolic reprograming, invasion, and metastasis are “cancer hallmarks” that are linked
to mitochondrial Ca2+ remodeling, which could be the prime reason for these transformations
(Figure 1).
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FIGURE 1 | The hallmarks of mitochondrial Ca2+ remodeling. This
illustration encompasses the six hallmarks of remodeled mitochondrial Ca2+
signaling that are involved in pathogenesis of some and perhaps all cancers.
Uncontrolled growth, programed cell death evasion, metabolic reprograming,
invasion, and metastasis are the “cancer hallmarks” that are linked to
mitochondrial Ca2+ remodeling, the prime reason of oncogenic behavior.
In this review, we will describe the current knowledge regard-
ing the role of mitochondrial Ca2+ signaling in cancer and the
rationale for targeting cancer cells withmitochondrial Ca2+mod-
ulators as a pharmacological therapeutic strategy.
Mitochondrial Ca2+ Homeostasis
Due to their strong electronegative potential (∆Ψ) and by topo-
logical organization, mitochondria are able to accumulate Ca2+
in the mitochondrial matrix. This organelle can generate contact
sites with the ER (13), where the channels responsible for Ca2+-
release (inositol trisphosphate receptor, IP3R) are juxtaposed to
mitochondrial Ca2+ handling/transport (14). Voltage-dependent
anion selective channels (VDACs) are permeable to Ca2+ and
are in the outer mitochondrial membrane (OMM), toward the
matrix-specific Ca2+ transporter, where these channels partici-
pate in structures devoted functionally to facilitating Ca2+-flow
toward the mitochondrion (15). This flow allows the generation
of a high [Ca2+] microdomain that is sufficient to trigger the
opening of mitochondrial uniporter complex (16). MCU is a two-
transmembrane domain protein that spans across the mitochon-
drial inner membrane, oligomerizing it to form the Ca2+-channel
portion of the complex (9, 10), and where it can accommodate the
MCU paralog MCUb. This protein does not exhibit any channel-
forming activity and may behave as a negative regulator of MCU
complex (17). MCU/MCUb oligomers physically interact with
two regulators located in the intermembrane space, MICU1 and
MICU2. Silencing studies have indicated that both regulators
participate in setting the Ca2+-threshold formitochondrial Ca2+-
uptake (18–20). Finally, the MCU regulator EMRE mediates the
interaction between MCU oligomers and MICU1/MICU2 (16).
The accumulation of Ca2+ requires efficient mechanisms to
turn off the signal to prevent the mitochondrial permeability
transition pore (mPTP) opening. The most well-characterized
Ca2+-efflux mechanism involves the mitochondrial Na+/Ca2+
exchanger (21). This protein forms dimers that transport either
Na+ or Li+ in exchange for Ca2+. Then, accumulated Na+
is extruded via mitochondrial Na+/H+ exchange. This activity
induces the dissipation of ∆Ψ, causingmitochondrial Ca2+-efflux
(22). In contrast, a non-electrogenic Ca2+/2H+ exchange has
been proposed to be responsible for Ca2+-efflux in non-excitable
cells. Its molecular identity has been proposed to be leucine
zipper-EF-hand containing transmembrane protein 1 (LETM1)
(23). Ongoing discussions have proposed that mPTP could be a
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component of the Ca2+-efflux system due to the involvement of
a non-specific channel that has been identified as the C subunit
of mitochondrial F1/FO ATP synthase (24). The manipulation
of C subunit expression is able to promote or inhibit mPTP
opening without affecting the physiological mitochondrial Ca2+
homeostasis (25).
Mitochondrial Ca2+ Homeostasis during
Proliferation and Cell Death
Cancer is sustained by defects in the mechanisms underlying cell
proliferation and cell death, and mitochondrial Ca2+ ions are
central to both events (Figure 1).
To meet the increased energy demand of cells during prolif-
eration, mitochondria utilize fundamental pathways for energy
metabolism, including the citric acid cycle (TCA) and oxidative
phosphorylation. An increase in mitochondrial ATP levels was
shown to occur in parallel with an evoked increase in mito-
chondrial [Ca2+] (26). The first results were obtained by Denton
andMcCormack, who showed thatmitochondrial Ca2+-activated
dehydrogenase enzymes led to increased NADH and thus ATP
production (27, 28). The involvement of different mitochondrial
targets in the regulation of oxidative phosphorylation by Ca2+,
including dehydrogenase activity, F1-F0-ATPase, and mitochon-
drial substrate-transport has been proposed (29).
Three are the mitochondrial dehydrogenase sensitive to Ca2+
of TCA: Pyruvate dehydrogenase (PDH), isocitrate dehydroge-
nase and α-ketoglutarate dehydrogenase. All of these molecules
exhibit different Ca2+-dependent mechanisms, suggesting that
the origins or specific activation signals are quite dissimi-
lar. Although the deregulation of mitochondrial metabolism
is intimately linked to oncogenic behavior, the role of cellu-
lar metabolism in oncogene-induced transformation is unclear.
Recently, the mitochondrial gatekeeper PDH was shown to be a
crucial mediator of oncogene-induced senescence promoted by
BRAF (V600E), which is the oncogene that is commonly mutated
in tumors (30).
The efficient mitochondrial respiration and maintenance of
normal cell bioenergetics require basal constitutive low-level Ca2+
signaling to sustain the mitochondrial Ca2+-uptake provided
by IP3R (31). The enhanced resistance to apoptosis of cancer
cells may involve its downregulated expression or activation,
compromising IP3R-mediated Ca2+ release. Indeed, in bladder
cancer cells, the acquisition of cisplatin resistance was sustained
by the drug-induced downregulation of IP3R1 expression (32).
Additionally, the disruption of IP3R-mediated ER–mitochondria
crosstalk compromised the production of mitochondrial ATP,
increasing the AMP/ATP ratio, which subsequently activated the
energy sensor AMP-activated protein kinase, inducing autophagy
(33, 34). This cascade of events occurs in advanced cancer under
hypoxic and nutrient-deficient conditions that activate autophagy
as a pro-survival mechanism (35).
The failure of mitochondria to take-up Ca2+ results in a failed
intracellular Ca2+ buffering with consequent aberrant activa-
tion of cytosolic Ca2+-dependent enzymes, such as calpain pro-
teases (36) and calmodulin-dependent kinases (37). In turn, these
enzymes alter cellular signaling cascades with consequent effects
on cell growth (38) or lead to increased glycolysis and tumor
cell invasion (39). However, the activation of calcineurin protein
phosphatase by increased cytosolic Ca2+ leads to the dephospho-
rylation of IκBβ and successiveNF-κB activation (40), which pro-
mote apoptosis resistance and cell migration (41). The migratory
capacity of tumor cells is linked with mitochondria morphology
(42, 43). In breast cancer, higher fragmented mitochondria con-
tent correlates with metastatic potential and the cell’s ability to
migrate and invade is significantly reduced when the Dynamin-
related protein 1 is silenced. The relationship between mitochon-
drial shaping and Ca2+ is well represented by the involvement of
Rho-GTPase Miro and by Drp1 [as reviewed in Ref. (44, 45)].
Endoplasmic reticulum–mitochondria contact sites allow the
accumulation of Ca2+ in response to not only physiological ago-
nists but also in response to apoptotic stimuli that induce ER
Ca2+-release (46). While moderate Ca2+ levels are essential for
normal mitochondrial activities, mitochondrial Ca2+ overload
is detrimental to mitochondrial morphology, causing mitochon-
drial permeabilization andorganelle swelling, with the consequent
release of pro-apoptotic factors (6). Recently, mitochondrial Ca2+
overload has also been implicated in mitophagy, the selective
degradation of damaged mitochondria (45).
A critical link between Ca2+ and apoptosis was established by
the oncoprotein Bcl-2. Evidence show that it reduces the filling
state of intracellular Ca2+-stores, reducing the Ca2+ signaling
evoked by physiological and pathological stimuli, but this obser-
vation is still debated (47, 48). Bcl-2 is also a critical regulator of
IP3R and interacts directly with this molecule to inhibit channel
opening and ER Ca2+-release, thereby assuring Ca2+-dependent
cell proliferation and apoptosis protection (49, 50). The mecha-
nism by which Bcl-2 family members control apoptosis remains
unclear; however, their activity involves controlling OMM per-
meability, which also requires interactions with OMM proteins
such as VDACs (51). Pro-apoptotic proteins of the Bcl-2 family
(such as Bax) exert opposite effects (i.e., a potentiation of Ca2+-
mediated signals) counteracting the effects of Bcl-2 on ER Ca2+
filling (52).
Voltage-dependent anion-selective channels are readily per-
meable to Ca2+ and can interact with IP3Rs at the ER (53).
VDACs are expressed in three isoforms that have common chan-
neling properties but different roles in cell survival (54, 55).
Although all three VDAC isoforms are equivalent in facilitating
mitochondrial Ca2+-uptake upon agonist stimulation, VDAC1
is preferentially involved in the transmission of low-amplitude
apoptotic Ca2+ signals to mitochondria. VDAC1 gene expression
levels are predictors of poor outcome in NSCLC and in other
cancers (56). VDACs are subjected to multiple levels of regula-
tion, including expression levels, post-translational modification,
and protein–protein interactions, all of which can limit Ca2+-
uptake. For example, VDAC may inhibit apoptosis, promoting
tumorigenesis and glycolysis through specific interactions with
hexokinase-2 (HK2). The upregulation ofHK expression in tumor
cells and its binding to VDAC provide both metabolic benefits
and apoptosis-suppressive capacity, offering advantages in terms
of growth and resistance to chemotherapy (57, 58). Mitochondrial
HK2 interferes with the ability of Bax to bind tomitochondria and
release cytochrome c, thus antagonizing cell death (59).
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Mitochondria are also the critical sites for “apoptotic” Ca2+
signaling due to MCU, which is responsible for low-affinity
Ca2+-uptake, influencing amyriad of Ca2+-dependent processes,
including cell death (60). MCU-overexpressing cells treated with
apoptotic stimuli, such as H2O2 and ceramide, exhibited more
pronounced apoptotic responses (10), while the overexpression
of a MCU-targeting microRNA miR-25 in colon cancer cells
impaired mitochondrial Ca2+-uptake and increased apoptosis
resistance (61). Thus, MCU appears to be a crucial protein for
tumorigenesis, and its specific pharmacological activators, if iden-
tified, could become a useful tool.
Much remains to be understood regarding the additional sig-
nals that converge on mitochondria and switch their function
to apoptotic inducers. These organelles can handle large Ca2+
loads under physiological conditions (e.g., in cardiac myocytes,
significant amounts of Ca2+ accumulate in mitochondria with
every heartbeat) with no deleterious effects. Oxidative stress is
considered an important factor for additional “apoptotic sig-
nal” (62, 63). ROS is involved in the regulation of physiologi-
cal processes but may also be harmful if produced excessively
by oxidative phosphorylation. A feature of transformed cells is
increased mitochondrial ROS levels, which are attributed to inef-
ficiencies in electron transport at the respiratory chain, increased
metabolic demand, reduced ROS scavenging, oncogene-induced
replicative stress, and altered mitochondrial dynamics (64, 65).
Indeed, ROS promote tumorigenesis in numerous ways, including
the stabilization of hypoxia-inducible factor HIF-α, the induc-
tion of oxidative base damage to mtDNA, the activation of both
NRF2 and NF-kB transcription factors, and the alteration of Ca2+
flux (66).
Alterations to Mitochondrial Ca2+
Homeostasis in Cancer Cells
Agrowing number of tumor suppressor genes and oncogenes have
been investigated due to their ability to regulate mitochondrial
function, influencing the physiological processes of this organelle
and its capacity to uptake Ca2+.
Among these genes, increasing evidence has highlighted the
role of the oncogene Ras in the growth and maintenance of the
tumor environment (67). The first link between mitochondria
and Ras is represented by the direct translocation of Ras into the
organelle, where the phosphorylated form exerts apoptotic activity
(68). Although some evidence has suggested a possible role of
mitochondria in the regulation of Ras-driven modifications, a
clear molecular mechanism underlying this relationship has not
yet been addressed. The oncogenic function of Ras facilitates
Stat3 translocation to mitochondria, which promotes mtDNA
transcription (69), and Ras-dependent mitochondrial dysfunc-
tion causes metabolic changes and ROS, which promote tumor
development (70). A direct link between Ca2+ regulation and
oncogenic Ras has been shown by Rimessi et al., in which H-
Ras affects the correct transmission of Ca2+ waves from the
ER to mitochondria (71). As a result, mitochondrial metabolism
and apoptosis are deeply compromised, and a neoplastic pheno-
type is induced. Recently, cancer stem cells in pancreatic cancer
were shown to survive oncogenic K-Ras ablation by relying on
oxidative phosphorylation (72) and by exhibiting high sensitiv-
ity to oxidative phosphorylation inhibitors to prevent tumors.
This finding is consistent with other recent reports referring to
leukemia cancer cells (73–75).
Additionally, the oncogene AKT regulates cell growth and
apoptosis, and upon PI3K stimulation, it rapidly accumulates
in mitochondria (76), where it inhibits apoptosis in an HK-
dependent manner (77, 78). AKT phosphorylates several pro-
apoptotic proteins, such as Bad and Bax, inhibiting their cell
death functions. AKT also phosphorylates HK2, promoting bind-
ing with VDAC1, and preventing a Ca2+-dependent apoptotic
response (79). In addition, AKT phosphorylates the IP3R iso-
forms that inhibit ER Ca2+ release and apoptosis, avoiding mito-
chondrial Ca2+ overload (80), preferentially phosphorylating the
IP3R3 (81). AKT is intimately regulated by the tumor suppressor
protein phosphatase and tensin homolog (PTEN), commonly lost
or mutated in human cancers (82). PTEN was demonstrated to
perform its growth-attenuating activity by regulating ER Ca2+
release via IP3R3. In this study, PTEN was shown to directly
interact with IP3R, counteracting the reduced IP3R-dependent
Ca2+ releasemediated byAKTphosphorylation in a phosphatase-
dependent manner (83). Another tumor suppressor that found
to downregulate the anti-apoptotic features of AKT is PML. This
tumor suppressor, where its tumoral behavior is regulated by
PIAS1 and SUMOylationmachinery (84), promotes the formation
of a multiprotein complex containing IP3R3, AKT, and the pro-
tein phosphatase PP2a, orchestrating ER–mitochondria Ca2+ flux
(85). An other example is the tumor suppressor BRCA1, recruited
to the ER during apoptosis in an IP3R-dependent manner, sensi-
tizing the IP3R to its ligand (86).
Additionally, the tumor suppressor p53 can regulate tumorige-
nesis in a Ca2+-dependent pathway. Different reports have docu-
mented the ability of p53 to regulate cell fate via post-translational
modifications (87, 88); however, p53 was recently shown to func-
tion in modulating Ca2+ transfer from ER to mitochondria. An
extranuclear pool of p53 interacts with the Ca2+-ATPase SERCA,
modulating Ca2+-dependent ER–mitochondria crosstalk, mito-
chondrial swelling and apoptosis induction (89, 90).
The tumor suppressor FHIT functions in a different man-
ner. This hydrolase, which acts as a tumor suppressor in vivo
and in vitro, enhances apoptosis susceptibility by acting directly
on the mitochondrial compartment. Specifically, FHIT increases
the affinity of the mitochondrial machinery for physiologi-
cal agonist- and apoptotic challenge-triggered Ca2+-uptake into
mitochondria (91).
Anti-Cancer Drugs Act on Mitochondrial
Ca2+ Homeostasis
The Ca2+ ion regulates various cellular processes, some of which
are involved in tumorigenesis and which are thus considered as
attractive drug targets for cancer therapy. Mitochondrial Ca2+
homeostasis may be affected by anti-cancer drugs that directly
influence mitochondria or targets that indirectly regulate mito-
chondrial Ca2+-uptake. Some of these drugs may affect mito-
chondrial Ca2+ uptake due to the depolarization of ∆Ψ. The
compounds included in this category are as follows: pancratistatin
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(a natural alkaloid exhibiting anti-cancer effects against human
colorectal adenocarcinoma xenografts (92) and colorectal
carcinoma cell lines, rhodamine-123 [the anti-cancer effects
of rhodamine-123 can be explained by its higher retention in
kidney and breast cancer cells compared to non-tumorigenic cells
(93, 94)], a naphthyridine derivative [4-phenyl-2,7-di(piperazin-
1-yl)-1,8-naphthyridine (95)], PMT7 [redox-active quinone
phloroglucinol derivative (96)], edelfosine [1-O-octadecyl-2-O-
methyl-racglycero-3-phosphocholine; its redistribution to the
mitochondria in HeLa cells causes mitochondrial depolarization
and apoptosis (97)], and many others that inhibit the mito-
chondrial respiratory chain that have been reviewed in detail by
Wen et al. (98).
Anti-cancer drugs can also influence the mitochondrial Ca2+-
uptake indirectly through the induction of ER stress. For example,
tunicamycin induces the accumulation of unfolded proteins in
the ER, which is known to enhance antitumor effects of different
chemotherapy drugs in vitro and in vivo (99). The cannabinoids
induce apoptosis of pancreatic tumor cells via the ER-stress-
related genes activating transcription factor 4 and TRB3 (100),
or by the photo-oxidative treatment with hypericin that causes
ER stress, induction of UPR target genes, and depletion of ER
Ca2+-stores (101). Brefeldin A blocks protein transport from the
ER to the Golgi apparatus (102), causes the deregulation of ER
Ca2+ homeostasis, or affects IP3R activity. Bortezomib, a selective
proteasome inhibitor approved for use in patients with multi-
ple myeloma, requires the mitochondrial uniporter as critical
regulatory factor for its cytotoxicity (103).
The anti-apoptotic Ca2+ effects of Bcl-2 are attributable to
direct interactions with IP3R through the BH4 domain (50, 104).
A peptide covering this residue was used to disrupt the IP3R/Bcl-
2-protein complex, enhancing the Ca2+-dependent apoptotic
response in a variety of tumoral cells (105–108).
TheHK–VDACcomplex is also an oncological target of erastin,
which is an antitumor agent that is selective for tumor cells
bearing oncogenic Ras (109), and of the chemo-potentiator 3-
bromopyruvate, which is an inhibitor of energy metabolism in
tumor cells (109, 110). Clotrimazole and bifonazole are also effec-
tive (111, 112), as is the anti-cancer agent furano naphthoquinone,
which induces a caspase-dependent apoptosis pathway through
ROS production (113).
The most direct effects of potential anti-cancer drugs on
mitochondrial Ca2+-uptake were obtained by potentiating MCU
complex expression/activity. Unfortunately, recent molecular
discoveries have impeded the identification of an MCU-specific
inducer. Alternative approaches could include MCU-targeting
anti-miRNA-based therapy and anti-miRNA 25 oligonucleotides
that could be used as potential agents against cancer (114).
Conclusion
“Uncontrolled growth, programed cell death evasion, metabolic
reprograming, invasion, and metastasis are ‘cancer hallmarks’
that are linked to mitochondrial Ca2+ remodeling, which could
be the prime reason for these transformations.” This specula-
tion in the Section “Introduction” is sustained by the knowledge
described thus far and by the most recent discoveries that high-
light the role of oxidative phosphorylation in tumor progression
andmaintenance. Previously,mitochondrial dysfunction has been
considered a consequence rather than a key player in tumor
development. Recently, cancer stem cells were shown to survive
oncogenic ablation by relying on oxidative phosphorylation (72),
and only mtDNA-depleted cancer cells were capable of recovering
mtDNA from host-formed metastasizing cancers in vivo (115),
thus highlighting the malicious capacity of tumor cells to acquire
mtDNA fromnormal bystander cells. Considering that the driving
force for mitochondrial Ca2+ internalization is ∆Ψ, which is
generated by respiratory chain, mitochondrial Ca2+ signaling has
become a prime factor that is responsible for oncogenic behavior.
Although mitochondrial Ca2+ remains a novel area of research
in oncology, considerable further work is required to clarify the
molecular mechanisms by which it contributes to cancer forma-
tion andmaintenance, and greater knowledge of this targetmay be
of importance in the development of new therapeutic strategies.
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